All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA 2018 | Durable responses seen with moxetumomab pasudotox in R/R HCL

By Sara Valente

Share:

Jul 25, 2018


On Saturday 16th June an oral abstract session took place at the 23rd Congress of the European Hematology Association (EHA). Abstract S856 was presented by Francis Giles, Developmental Therapeutics Consortium, Chicago, US, on the use of moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory (R/R) hairy cell leukemia (HCL) (NCT01829711).

Study Overview

  • The study was single-arm, open-label at 34 centers across 14 countries
  • N = 80 patients received 40 μg/kg IV on Days 1,3 and 5 of 28-day treatment cycles until disease progression or unacceptable toxicity
  • The primary endpoint was the rate of durable complete response (CR) that was defined by CR with hematologic remission of ≥181 days
  • The secondary endpoints were overall response rate (ORR), CR rate, progression-free survival (PFS), duration of response (DOR), tolerability and safety

Key Findings

  • The durable CR as assessed by a blinded independent review was 30% (95% CI, 20%–41%)
  • 34% (n = 27) of patients demonstrated CR with MRD-negativity according to immunohistochemistry (95% CI, 24%–45%)
  • The ORR as assessed by a blinded independent review was 75% (95% CI, 64%–84%)
  • 80% achieved hematologic remission with a median onset of 1.1 months
  • The median duration of hematologic remission from CR was not reached
  • Most frequent treatment-related adverse events (AEs) Grade ≥3 was lymphocyte count decrease (7.5%) and hemolytic uremic syndrome (5%)

The findings of this study demonstrated that moxetumomab pasudotox had durable responses in patients with R/R HCL. Dr Giles concluded that moxetumomab pasudotox also eradicated MRD in a substantial proportion of patients.

References

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?